Cost-effectiveness analysis of cefiderocol for the treatment of confirmed or suspected carbapenem-resistant Gram-negative bacteria serious infections

GONG Yuan; KANG Shuo; HOU Yibing; WANG Xiaohui; NIE Ying; WANG Jing; PAN Zhenhua

doi:10.6039/j.issn.1001-0408.2026.02.10

您当前的位置：

首页 >

文章列表页 >

Cost-effectiveness analysis of cefiderocol for the treatment of confirmed or suspected carbapenem-resistant Gram-negative bacteria serious infections

更新时间：2026-02-10

- Cost-effectiveness analysis of cefiderocol for the treatment of confirmed or suspected carbapenem-resistant Gram-negative bacteria serious infections
- ZHONGGUO YAOFANG Vol. 37, Issue 2, Pages: 192-197(2026)
- 作者机构：
  
  1.河北医科大学药学院，石家庄　050017
  2.河北医科大学第二医院医保科，石家庄　050061
  3.河北医科大学第二医院药学部，石家庄　050061
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.02.10
  CLC： R956
- Received：14 August 2025，
  
  Revised：2025-12-31，
  
  Accepted：06 January 2026，
  
  Published：30 January 2026
- 稿件说明：
移动端阅览
公元,康朔,侯奕冰,等.头孢地尔治疗确诊与疑似耐碳青霉烯类革兰氏阴性菌严重感染的成本-效果分析[J].中国药房,2026,37(02):192-197.

GONG Yuan,KANG Shuo,HOU Yibing,et al.Cost-effectiveness analysis of cefiderocol for the treatment of confirmed or suspected carbapenem-resistant Gram-negative bacteria serious infections[J].ZHONGGUO YAOFANG,2026,37(02):192-197.
公元,康朔,侯奕冰,等.头孢地尔治疗确诊与疑似耐碳青霉烯类革兰氏阴性菌严重感染的成本-效果分析[J].中国药房,2026,37(02):192-197. DOI： 10.6039/j.issn.1001-0408.2026.02.10.

GONG Yuan,KANG Shuo,HOU Yibing,et al.Cost-effectiveness analysis of cefiderocol for the treatment of confirmed or suspected carbapenem-resistant Gram-negative bacteria serious infections[J].ZHONGGUO YAOFANG,2026,37(02):192-197. DOI： 10.6039/j.issn.1001-0408.2026.02.10.

摘要

目的

从我国卫生体系视角出发，评估头孢地尔对比最佳可用疗法（BAT）或标准疗法（SOC）治疗确诊或疑似耐碳青霉烯类革兰氏阴性菌严重感染的经济性，并探讨其合理定价。

方法

基于两项Ⅲ期临床试验（CREDIBLE-CR与GAME CHANGER）数据构建决策树模型，模拟头孢地尔在确诊耐碳青霉烯类革兰氏阴性菌感染的救治场景（场景一）与疑似上述耐药菌感染的初始经验性治疗场景（场景二）下的成本-效果。主要结局指标为增量成本-效果比（ICER），意愿支付阈值设定为2024年我国人均国内生产总值（GDP）的1～3倍。采用单因素及概率敏感性分析检验结果的稳健性，并在此基础上探索头孢地尔在我国市场的合理定价区间。

结果

场景一的结果表明，头孢地尔组的治愈率高于BAT组（47.50% vs. 34.21%），但其ICER为415 065.03元/例治愈，超出3倍我国人均GDP的阈值；而场景二揭示，头孢地尔相对于SOC的ICER高达1 362 446.16元/例治愈，远超意愿支付阈值。敏感性分析表明，头孢地尔的治疗时间与价格是影响方案经济性的关键因素。在上述2个场景中，头孢地尔单价需分别降至683.47、242.00元/g以下方具经济性。

结论

基于当前市场价格，头孢地尔治疗确诊或疑似耐碳青霉烯类革兰氏阴性菌严重感染在我国卫生体系中的经济性不足，需通过价格谈判或医保分层支付策略提高其可及性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of cefiderocol versus best available therapy （BAT） or standard-of-care （SOC） for the treatment of confirmed or suspected carbapenem-resistant Gram-negative bacterial （CRGNB） serious infections from the perspective of the Chinese healthcare system， and to explore its reasonable pricing.

METHODS

A decision tree model was constructed based on data from two phase Ⅲ clinical trials （CREDIBLE-CR and GAME CHANGER） to simulate the cost-effectiveness of cefiderocol in two scenarios： salvage therapy for confirmed CRGNB infection （scenario 1） and empirical therapy for suspected CRGNB infection （scenario 2）. The primary outcome measure was the incremental cost-effectiveness ratio （ICER）. The willingness-to-pay （WTP） was set at 1 to 3 times China’s per capita GDP in 2024. To verify the robustness of the results， one-way and probabilistic sensitivity analyses were conducted， and based on these， a reasonable price range for cefiderocol in the Chinese market was explored.

RESULTS

The results for scenario 1 showed that the clinical cure rate in the cefiderocol group was higher than that in the BAT group （47.50% vs. 34.21%）， but its ICER was 415 065.03 yuan per cured case， exceeding three times China’s GDP per capita. Scenario 2 revealed that the ICER for cefiderocol relative to SOC was as high as 1 362 446.16 yuan per cured case， far exceeding the WTP. Sensitivity analysis indicated that the treatment duration and price of cefiderocol were key factors affecting its cost-effectiveness. In the two scenarios described above， the unit price of cefiderocol must fall below 683.47 and 242.00 yuan/g， respectively， to be considered cost-effective.

CONCLUSIONS

Based on the current market price， cefiderocol lacks sufficient cost-effectiveness for treating confirmed or suspected CRGNB serious infections within China’s healthcare system. To improve its accessibility， price negotiations or a tiered medical insurance payment strategy are required.

关键词

Keywords

references

IHME Pathogen Core Group . Global burden associated with 85 pathogens in 2019：a systematic analysis for the Global Burden of Disease Study 2019 [J ] . Lancet Infect Dis ， 2024 ， 24 （ 8 ）： 868 - 895 .

Antimicrobial Resistance Collaborators . Global burden of bacterial antimicrobial resistance in 2019：a systematic analysis [J ] . Lancet ， 2022 ， 400 （ 10358 ）： 1102 .

郭燕，丁丽，胡付品，等 . 2024年CHINET中国细菌耐药监测 [J ] . 中国感染与化疗杂志， 2025 ， 25 （ 6 ）： 597 - 607 .

曾玫，夏君，宗志勇，等 . 碳青霉烯类耐药革兰阴性菌感染的诊断、治疗及防控指南 [J ] . 中国感染与化疗杂志， 2024 ， 24 （ 2 ）： 135 - 151 .

ZHANEL G G ， GOLDEN A R ， ZELENITSKY S ， et al . Cefiderocol：a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli [J ] . Drugs ， 2019 ， 79 （ 3 ）： 271 - 289 .

WUNDERINK R G ， MATSUNAGA Y ， ARIYASU M ， et al . Cefiderocol versus high-dose，extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia（APEKS-NP）：a randomised，double-blind，phase 3，non-inferiority trial [J ] . Lancet Infect Dis ， 2021 ， 21 （ 2 ）： 213 - 225 .

SATO T ， YAMAWAKI K . Cefiderocol：discovery，chemistry，and in vivo profiles of a novel siderophore cephalo-sporin [J ] . Clin Infect Dis ， 2019 ， 69 （ Suppl 7 ）： S538 - S543 .

BASSETTI M ， ECHOLS R ， MATSUNAGA Y ， et al . Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria（CREDIBLE-CR）：a randomised，open-label，multicentre，pathogen-focused，descriptive，phase 3 trial [J ] . Lancet Infect Dis ， 2021 ， 21 （ 2 ）： 226 - 240 .

CLANCY C J ， CORNELY O A ， MARCELLA S W ， et al . Effectiveness and safety of cefiderocol in clinical practice for treatment of patients with Gram-negative bacterial infections：us interim results of the PROVE study [J ] . Infect Drug Resist ， 2024 ， 17 ： 4427 - 4443 .

PATERSON D L ， SULAIMAN H ， LIU P Y ， et al . Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection（the GAME CHANGER trial）：an open-label，parallel-group，randomised trial [J ] . Lancet Infect Dis ， 2025 ： S1473-S3099（25）00469 - 4 .

XUAN J W ， WANG L J ， YIN H J ， et al . The cost-effectiveness of OM-85 in managing respiratory tract infections in China [J ] . J Med Econ ， 2015 ， 18 （ 3 ）： 167 - 172 .

邓铭俊，刘水清，谢宏民，等 . 参苓白术散加减治疗脾虚湿热型溃疡性结肠炎的成本-效果分析 [J ] . 中国现代药物应用， 2023 ， 17 （ 10 ）： 140 - 142 .

ZHAN M ， HUANG Z J ， XU T ， et al . Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04 [J ] . Front Public Health ， 2023 ， 11 ： 1049947 .

KONG W Q ， YANG X T ， SHU Y F ， et al . Cost-effectiveness analysis of ceftazidime-avibactam as definitive treatment for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infection [J ] . Front Public Health ， 2023 ， 11 ： 1118307 .

LI M ， CAO Y X ， HUANG H ， et al . Cost-effectiveness analysis of antiretroviral drugs for treatment-naive HIV infection in China [J ] . BMC Public Health ， 2023 ， 23 （ 1 ）： 2228 .

梁虹艺，叶嘉盛，季波，等 . 基于决策树模型对国产与原研注射用盐酸万古霉素治疗MRSA感染的成本-效果分析 [J ] . 今日药学， 2021 ， 31 （ 9 ）： 702 - 707，712 .

马玲，郑鹏程，郑瑞，等 . 万古霉素与利奈唑胺在中国治疗耐甲氧西林金黄色葡萄球菌感染的医院获得性肺炎的成本-效果分析 [J ] . 中国医院药学杂志， 2019 ， 39 （ 22 ）： 2314 - 2318 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of cost-effectiveness of amivantamab combined with chemotherapy in the treatment of EGFR-mutated advanced non-small cell lung cancer

Cost-effectiveness analysis of gonadotropin-releasing hormone analogue combined with recombinant human growth hormone in the treatment of central precocious puberty

Cost-effectiveness analysis of sacituzumab tirumotecan versus single-agent chemotherapy in second-line and later-line treatment for metastatic triple-negative breast cancer

Clinical evaluation of elderly patients with sarcopenia receiving Shenling baizhu powder combined with nutrition and exercise intervention

Cost-effectiveness analysis of apatinib combined with adriamycin for second-line treatment of platinum-resistant recurrent ovarian cancer

Related Author

WANG Xianying

LIANG Miao

LIU Yang

LIU Jianing

LIU Zheng

ZENG Linan

WU Jin

YANG Chunsong

Related Institution

Dept. of Pharmacy， Hebei Medical University Third Hospital

Evidence-based Medicine Center， West China Hospital， Sichuan University

Molecular Translational Medicine Laboratory， Translational Medicine Center， Sichuan University

Dept. of Pediatrics， West China Second Hospital， Sichuan University

West China Clinical Medical College， Sichuan University

⁰